T세포 면역요법 시장 : 작용기전, 제품군, 치료 유형, 적응증별 - 세계 예측(2025-2030년)

The T-Cell Immunotherapy Market was valued at USD 6.81 billion in 2023, expected to reach USD 7.74 billion in 2024, and is projected to grow at a CAGR of 14.12%, to USD 17.17 billion by 2030.

T-cell immunotherapy is a transformative approach in cancer treatment, focusing on enhancing the body's immune system to combat diseases. This method involves modifying T-cells to identify and destroy cancer cells efficiently. The necessity of this therapy arises due to the limitations and adverse effects of traditional cancer treatments like chemotherapy and radiation. Its application predominantly spans hematologic cancers, though recent innovations are expanding its use to solid tumors as well. Key end-users include hospitals, cancer treatment centers, and research institutes. Market growth is propelled by increasing cancer incidences, advancements in gene-editing technologies, and the success of therapies like CAR-T and TCR-T. Funding from government and private entities also stimulates market dynamics. Emerging opportunities lie in the development of allogeneic therapies, which promise reduced costs and enhanced accessibility. Collaborations and partnerships with biotech firms to innovate and enhance therapy efficacy can provide a competitive edge. However, challenges such as high treatment costs, complexities in manufacturing processes, and stringent regulatory requirements can hinder growth. Additionally, logistical challenges, including the need for personalized treatment, also pose significant constraints. To overcome these obstacles, enhancing production technologies and focusing on cost-effective methods are crucial. There is a growing need for research in understanding tumor microenvironments and improving the specificity of T-cells to reduce unintended side effects. The market exudes a dynamic nature, characterized by rapid technological innovations, intense competition, and evolving regulatory landscapes. The best areas of innovation include developing next-generation T-cell therapies that can target a wider range of tumors and enhancing the safety profiles of existing therapies. By focusing on these areas, companies can seize opportunities to advance T-cell immunotherapy and enjoy significant growth and success in this rapidly evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Immunotherapy Market

The T-Cell Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Cancer and Autoimmune Diseases
  • Use of Cell-Based Targeted Therapies
  • Increasing R&D Supporting T-cell Immunotherapy
• Market Restraints
  • High Cost of Treatment
• Market Opportunities
  • Commercialisation and Funding by Pharmaceutical Companies
  • Attractiveness of Off-the-Shelf Therapies
• Market Challenges
  • Neurologic Toxicities and Cytokine Release Syndrome

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Immunotherapy Market

A detailed market share analysis in the T-Cell Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Immunotherapy Market

A strategic analysis of the T-Cell Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the T-Cell Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Mechanism Of Action, market is studied across Active Immunotherapy and Passive Immunotherapy.
• Based on Product Class, market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
• Based on Type of Therapy, market is studied across CAR-T, TCR, and TIL.
• Based on Indication, market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
    • 5.1.1.2. Use of Cell-Based Targeted Therapies
    • 5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
    • 5.1.3.2. Attractiveness of Off-the-Shelf Therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. T-Cell Immunotherapy Market, by Mechanism Of Action

• 6.1. Introduction
• 6.2. Active Immunotherapy
• 6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class

• 7.1. Introduction
• 7.2. Bispecific Antibodies
• 7.3. Cytokines
• 7.4. Monoclonal Antibodies
• 7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy

• 8.1. Introduction
• 8.2. CAR-T
• 8.3. TCR
• 8.4. TIL

9. T-Cell Immunotherapy Market, by Indication

• 9.1. Introduction
• 9.2. B-cell Malignancies
• 9.3. Liver Cancer
• 9.4. Prostate Cancer
• 9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptimmune Therapeutics PLC
• 2. Alaunos Therapeutics, Inc.
• 3. Apac Biotech
• 4. Atara Biotherapeutics, Inc.
• 5. Autolus Therapeutics PLC
• 6. bluebird bio, Inc.
• 7. Bristol-Myers Squibb Company
• 8. CARsgen Therapeutics Holdings Limited
• 9. Cellectis SA
• 10. Chimera Bioengineering
• 11. Dendreon Pharmaceuticals LLC
• 12. Eureka Therapeutics, Inc.
• 13. Gilead Sciences, Inc.
• 14. Green Cross Corporation
• 15. Innovative Cellular Therapeutics
• 16. Iovance Biotherapeutics, Inc.
• 17. LAVA Therapeutics N.V.
• 18. Lyell Immunopharma, Inc.
• 19. Neogene Therapeutics, Inc.
• 20. NeoTX Therapeutics Ltd.
• 21. Novartis AG
• 22. Oxford Vacmedix UK Limited
• 23. Poseida Therapeutics, Inc.
• 24. TScan Therapeutics, Inc.
• 25. Xenetic Biosciences, Inc.